bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.08.01.742197

COGNITIVE DETERIORATION IS REVERSED BY AN INSULIN-LIKE GROWTH FACTOR 1 SENSITIZER IN A MOUSE MODEL OF ALZHEIMER DISEASE

Zegarra-Valdivia, J. A.·Khan, Z. M.·Vega, M.·Torres Aleman, I.
View original source ↗Export metadata ↓

Abstract

Previous observations in preclinical and clinical studies indicate a beneficial effect of insulin-like growth factor 1 (IGF-1) in different neurological illnesses, including Alzheimers disease (AD). AD is the most important neurodegenerative disease in the world and despite previous intensive research and the recent approval of putative disease-modifying therapies, available treatments provide only modest clinical benefit and do not halt disease progression. Consequently, there remains a pressing need to develop novel therapeutic strategies for AD. Since resistance to IGF-1 may be involved in development of AD, as it regulates cognition and amyloid {beta} (A{beta}) metabolism, we recently developed a small molecule IGF-1 sensitizer, AIK3a305, that crosses the blood brain barrier (BBB) and exerts modulatory actions in the brain. Using a mouse model of familial AD, the APP/PS1 mouse, we administered them AIK3a305 for 3 months. Treatment started at 12 months of age, when the disease is already well established, and cognitive deterioration readily measurable. One month after starting daily intraperitoneal injections of AIK3a305, mice showed normal cognitive performance in the Y maze, a measure of working memory that enables daily life activities. After 3 months, cognition remained fully preserved, mood-associated disturbances such as anxiety, were corrected, and brain A{beta} levels significantly ameliorated. AIK3a305 may therefore be a promising novel therapeutic strategy for AD patients.

Explore related subjects

neurosciencePreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zegarra-Valdivia, J. A., Khan, Z. M., Vega, M., Torres Aleman, I.. 2026-08-06. COGNITIVE DETERIORATION IS REVERSED BY AN INSULIN-LIKE GROWTH FACTOR 1 SENSITIZER IN A MOUSE MODEL OF ALZHEIMER DISEASE. https://doi.org/10.64898/2026.08.01.742197

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A systems-level model of sleep-dependent memory-consolidation failure in neurodegeneration: the spindle-slow-oscillation decoupling cascade dissociates amyloid and tau

During non-rapid-eye-movement (NREM) sleep, the temporal coupling of cortical slow oscillations (SOs), thalamic spindles, and hippocampal sharp wave ripples drives the consolidation of declarative memories. This coupling degrades in ageing and Alzheimers disease (AD), and although A{beta} and tau leave dissociable signatures in human sleep, the mechanisms by which progressive pathology dismantles the consolidation machinery are difficult to isolate experimentally, and have not to our knowledge been reproduced in a model that can be perturbed directly. We built a systems-level model in which cortical SOs and thalamic spindles are generated by reduced oscillators, hippocampal ripples replay encoded spike sequences, and the measured per-event SO-spindle timing alignment causally gates spike-timing dependent plasticity on cortical sequence synapses. A post-sleep cued-recall test reads out consolidation. Five neurodegeneration parameters (amyloid, tau, synaptic density, GABAergic inhibition, cholinergic tone) map to dis tinct mechanisms grounded in the human and animal literature. The model reproduces graded healthy consolidation and a progressive collapse in which coupling, slow-wave power, spindle power and recall fall monotonically and the overnight memory effect flips from consolidation to net forgetting, with weak memories failing first. Scrambling SO-spindle timing while holding oscillation power fixed abolishes consolidation, establishing that coupling timing, rather than oscillation power, is what the plasticity gate depends on within the model. A{beta} and tau impair memory through orthogonal signatures (A{beta} collapses slow-wave power while sparing replay order, tau the reverse) and this orthogonality holds across the entire A{beta} x tau plane and survives simultaneous {+/-}50% resampling of every mapping coefficient (40/40 samples), so it is not an artefact of a single calibration point. The model yields a falsifiable clinical prediction: closed-loop slow-oscillation enhancement rescues memory only when the deficit is amplitude/coupling-dominated, not when it is replay(tau)-dominated, despite normalising slow-wave power in both cases. Because the therapy arms dissociate coupling from memory benefit, the model also cautions against adopting SO-spindle coupling as a standalone surrogate endpoint.

neuroscience↗
bioRxiv2026

Toxicity of MAPT 4R RNA Contributes to Motor Neuron Degeneration in ALS

MAPT (Tau) dysregulation is implicated in several neurodegenerative diseases, but its contribution to amyotrophic lateral sclerosis (ALS) is poorly understood. Here we show that mRNA isoforms encoding 4-repeat (4R) Tau are upregulated and cytoplasmically enriched in iPSC-derived motor neurons (MNs) from VCP-mutant and sporadic ALS, without a corresponding change in Tau protein. Using splice-switching antisense oligonucleotides and isoform-specific siRNAs, we find that enhanced 4R expression reduces MN viability, whereas its selective knockdown improves survival, with kinetics more consistent with an RNA-intrinsic effect than altered protein synthesis. Exon 10-containing MAPT RNA shows increased predicted secondary structure, self-association and altered Tau biocondensation in vitro. In post-mortem ALS cervical spinal cord, increased relative exon 10 usage is associated with a higher-risk clinical phenotype and shorter disease duration These findings identify an isoform-specific contribution of MAPT to MN vulnerability in ALS and nominate 4R MAPT RNA as a therapeutic target.

neuroscience↗
bioRxiv2026

30 Hz High-Definition Transcranial Alternating Current Stimulation at the Left Frontal Cortex Reduces the Spectral Slope of the EEG in the Contralateral Hemisphere

Background: High-definition transcranial alternating current stimulation (HD-tACS) is favored by the neurostimulation community for its precision and ability to influence neuronal dynamics. Yet, the exact mechanism by which the underlying brain structures are being affected remains unclear. We believe that the investigation of the aperiodic nature of the electroencephalograph (EEG) could shed light on the modulatory effects of HD-tACS. Methods: We analyzed the EEG of 9 participants during a compensatory tracking task (CTT) in two sessions, each with different HD-tACS protocols. Every session consisted of an initial period of no stimulation, followed by 30 Hz HD-tACS in the left motor (M30) or frontal (F30) cortex. We then isolated the aperiodic component of the EEG and calculated its spectral slope {beta}. Results and Discussion: {beta} decreased during F30 mainly in the right frontal cortex, indicating a shift towards higher frequencies and an increase of the excitatory/inhibitory balance. Additionally, we found that despite the long monotonus task the accuracy of the participants did not decrease, which might be attributed to the ability of both M30 and F30 to sustain attention for prolonged time. Finally, the change of CTT accuracy during the stimulation correlated with the {beta} of specific channels before the stimulation. This indicates the potential of {beta} to be used as a screening biomarker in future studies. In conclusion, we showed the ability of HD-tACS to alter EEG aperiodic dynamics and paved the way for future exploration of such dynamics in the field.

neuroscience↗